US Bancorp’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-253
| Closed | -$6.1K | – | 4201 |
|
|
2023
Q1 | $6.1K | Buy |
253
+86
| +51% | +$1.08K | ﹤0.01% | 3457 |
|
|
2022
Q4 | $1.76K | Buy |
+167
| New | +$1.35K | ﹤0.01% | 3806 |
|
|
2022
Q3 | – | Sell |
-3,000
| Closed | -$12K | – | 4277 |
|
|
2022
Q2 | $12K | Sell |
3,000
-521
| -15% | -$2.47K | ﹤0.01% | 3323 |
|
|
2022
Q1 | $26K | Hold |
3,521
| – | – | ﹤0.01% | 2942 |
|
|
2021
Q4 | $20K | Sell |
3,521
-2,931
| -45% | -$18.6K | ﹤0.01% | 3124 |
|
|
2021
Q3 | $41K | Buy |
6,452
+213
| +3% | +$1.37K | ﹤0.01% | 2742 |
|
|
2021
Q2 | $53K | Buy |
6,239
+1,239
| +25% | +$10K | ﹤0.01% | 2646 |
|
|
2021
Q1 | $52K | Buy |
5,000
+2,000
| +67% | +$28.1K | ﹤0.01% | 2569 |
|
|
2020
Q4 | $51K | Hold |
3,000
| – | – | ﹤0.01% | 2508 |
|
|
2020
Q3 | $38K | Hold |
3,000
| – | – | ﹤0.01% | 2533 |
|
|
2020
Q2 | $42K | Hold |
3,000
| – | – | ﹤0.01% | 2504 |
|
|
2020
Q1 | $28K | Hold |
3,000
| – | – | ﹤0.01% | 2619 |
|
|
2019
Q4 | $45K | Hold |
3,000
| – | – | ﹤0.01% | 2524 |
|
|
2019
Q3 | $20K | Hold |
3,000
| – | – | ﹤0.01% | 2851 |
|
|
2019
Q2 | $36K | Buy |
+3,000
| New | +$16.3K | ﹤0.01% | 2679 |
|
Other funds holding PRVB
US Bancorp's PRVB Position: Q2 2023 in Review
US Bancorp sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 253 shares — an estimated $6.1K sold.
US Bancorp first reported a position in PRVB in Q2 2019 and held it in 15 quarters. The position peaked at $53K in Q2 2021. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- US Bancorp reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- US Bancorp sold 253 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $6.1K.
- US Bancorp first reported a position in Provention Bio, Inc. Common Stock in Q2 2019 and held it in 15 quarters.
- US Bancorp's Provention Bio, Inc. Common Stock position peaked at $53K in Q2 2021.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on US Bancorp's 13F filing for Q2 2023, filed 10 Aug 2023.